Article: Nicotinamide Riboside Mitigates Diabetes-Related Bone Loss: Preclinical Findings

Jan 28, 2025 Bone Health Diabetes Metabolic Health Preclinical

Nicotinamide Riboside Mitigates Diabetes-Related Bone Loss: Preclinical Findings

Synopsis

Type 2 diabetes mellitus (T2DM) caused by high-fat diet/streptozotocin treatment led to impaired bone microarchitecture and bone loss in mice, along with metabolic dysfunction. Supplementation with nicotinamide riboside (NR) improved insulin resistance, enhanced bone structure and quality, reduced bone resorption, activated the FOXO signaling pathway, suppressed NF-κB–mediated inflammation, and corrected defects in oxidative phosphorylation (OXPHOS). These findings show that NR mitigates diabetes-induced osteoporosis primarily by restoring mitochondrial metabolism and regulating key bone signaling pathways, highlighting its potential as a therapeutic strategy for T2DM-related bone disease. Further validation in diabetic osteoblasts and osteoclasts is warranted.

Journal

Bone

See Published Study

Liver Health

Nicotinamide Riboside Protects Liver Cells from Palmitate-Induced Damage: Preclinical Findings

Synopsis This study examined how excessive fat buildup in liver cells (hepatic lipotoxicity) contributes to liver damage, a key factor in metabolic liver diseases. Researchers found that exposure ...